KLMab-1: An Anti-human KLRG1 Monoclonal Antibody for Immunocytochemistry

Area of Science:

• Immunology
• Cancer Research
• Monoclonal Antibody Development

Background:

• Immune checkpoint molecules are crucial targets for cancer immunotherapy.
• Killer cell lectin-like receptor subfamily G member 1 (KLRG1) is an immune checkpoint molecule found on T and NK cells.
• KLRG1 plays a role in antiviral and antitumor immunity, with upregulated expression in certain diseases and tumors.

Purpose of the Study:

• To develop and validate monoclonal antibodies (mAbs) against human KLRG1 (hKLRG1) for diagnostic and therapeutic applications.
• To assess the utility of anti-hKLRG1 mAbs in detecting both exogenous and endogenous hKLRG1.

Main Methods:

• Development of anti-hKLRG1 mAb (clone KLMab-1) using Cell-Based Immunization and Screening.
• Immunocytochemistry to evaluate mAb binding to exogenous hKLRG1 in CHO-K1 cells.
• Flow cytometry to confirm detection of endogenous hKLRG1 in human NK cells.

Main Results:

• The developed anti-hKLRG1 mAb (KLMab-1) and its recombinant version (recKLMab-1) successfully bound to exogenous hKLRG1.
• Both mAbs demonstrated the ability to detect endogenous hKLRG1 expressed in human NK cells.
• The study confirmed the availability of KLMab-1 and recKLMab-1 for immunocytochemistry applications.

Conclusions:

• KLMab-1 and recKLMab-1 are validated tools for detecting human KLRG1.
• These antibodies show potential for use in the diagnosis and immunotherapy of viral diseases and cancers.
• The findings support the utility of anti-KLRG1 antibodies in immunological research and clinical applications.